PMID- 36522475
OWN - NLM
STAT- MEDLINE
DCOM- 20230303
LR  - 20230315
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 128
IP  - 5
DP  - 2023 Mar
TI  - Association between atherogenic lipids and GnRH agonists for prostate cancer in 
      men with T2DM: a nationwide, population-based cohort study in Sweden.
PG  - 814-824
LID - 10.1038/s41416-022-02091-z [doi]
AB  - BACKGROUND: Gonadotropin-releasing hormone agonists (GnRH) used in prostate 
      cancer (PCa) are associated with atherogenic dyslipidaemia. It can be assumed 
      that GnRH need to be used with greater caution in men with type 2 diabetes 
      mellitus (T2DM). This study investigated association of GnRH with atherogenic 
      lipids (AL) in PCa men with T2DM. METHODS: Two cohorts including 38,311 men with 
      11 years follow-up based on Swedish national registers were defined (PCa-Exposure 
      cohort and GnRH-Exposure cohort). Based on European guidelines on cardiovascular 
      diseases (CVD), primary outcomes were defined as: 1.0 mmol/L increase in AL and 
      lipid-lowering therapy (LLT) intensification. We used Cox proportional-hazards 
      models and Kaplan-Meier curves to assess the association. RESULTS: There was an 
      association between GnRH and increased AL (i.e., triglyceride, PCa-Exposure 
      cohort: HR 1.77, 95% CI 1.48-2.10; GnRH-Exposure cohort: HR 1.88, 95% CI 
      1.38-2.57). There was also an association between PCa diagnosis and increased AL. 
      In contrast, no association between LLT intensification and GnRH was found. 
      CONCLUSION: In this large population-based study, men with T2DM on GnRH for PCa 
      had an increased risk of increased atherogenic lipids. These results highlight 
      the need to closely monitor lipids and to be ready to intensify lipid-lowering 
      therapy in men with T2DM on GnRH for PCa.
CI  - (c) 2022. The Author(s).
FAU - Lin, E
AU  - Lin E
AUID- ORCID: 0000-0002-1710-1866
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, London, UK. e.lin@kcl.ac.uk.
FAU - Garmo, Hans
AU  - Garmo H
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, London, UK.
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Hagstrom, Emil
AU  - Hagstrom E
AUID- ORCID: 0000-0003-3221-0144
AD  - Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
AD  - Uppsala Clinical Research Centre, Uppsala, Sweden.
FAU - Van Hemelrijck, Mieke
AU  - Van Hemelrijck M
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, London, UK.
FAU - Adolfsson, Jan
AU  - Adolfsson J
AD  - Department of Clinical Science, Intervention and Technology, Karolinska 
      Institute, Stockholm, Sweden.
FAU - Stattin, Par
AU  - Stattin P
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Zethelius, Bjorn
AU  - Zethelius B
AD  - Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
FAU - Crawley, Danielle
AU  - Crawley D
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, London, UK.
LA  - eng
GR  - C45074/A26553/Cancer Research UK (CRUK)/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221215
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
RN  - 0 (Lipids)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - Sweden
MH  - Cohort Studies
MH  - Gonadotropin-Releasing Hormone
MH  - *Prostatic Neoplasms/diagnosis
MH  - Lipids
PMC - PMC9977763
COIS- The authors declare no competing interests. BZ is employed at the Swedish Medical 
      Products Agency, SE-751 03 Uppsala, Sweden. The views expressed in this paper are 
      the personal views of the authors and not necessarily the views of the Swedish 
      government agency.
EDAT- 2022/12/16 06:00
MHDA- 2023/03/04 06:00
PMCR- 2022/12/15
CRDT- 2022/12/15 23:31
PHST- 2022/01/07 00:00 [received]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2022/11/15 00:00 [revised]
PHST- 2022/12/16 06:00 [pubmed]
PHST- 2023/03/04 06:00 [medline]
PHST- 2022/12/15 23:31 [entrez]
PHST- 2022/12/15 00:00 [pmc-release]
AID - 10.1038/s41416-022-02091-z [pii]
AID - 2091 [pii]
AID - 10.1038/s41416-022-02091-z [doi]
PST - ppublish
SO  - Br J Cancer. 2023 Mar;128(5):814-824. doi: 10.1038/s41416-022-02091-z. Epub 2022 
      Dec 15.